Anti-inflammatory: new trends in the treatment of the patient with systemic sclerosis.
The treatment of systemic sclerosis is a difficult challenge because of the present lack of drugs definitely proven to alter the overall course of the disease. To address the current guidelines and to analyze the perspectives opened by the availability of new drugs and the identification of previously unknown pathways. The statements on current treatment are based on recently developed EULAR recommendations. The perspectives reflect the opinion of the authors on emerging topics. The treatment of systemic sclerosis has improved in recent years because a number of drugs have been shown to influence single disease manifestations. The identification of previously unknown pathways might open the way for further developments.